C4 Therapeutics Debt to Equity

The latest debt-to-equity ratio for CCCC is 0.34. That is above the Healthcare sector average of 0.27. Investors often review this figure alongside C4 Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, CCCC currently prints 0.34 for debt-to-equity ratio, while the sector average sits near 0.27. That is roughly 27.3% above the sector mean. Large gaps often invite a closer look at C4 Therapeutics's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.34 for C4 Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (0.27) and with CCCC's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CCCC's debt-to-equity ratio (0.34), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack C4 Therapeutics's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.